In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PhotoCure grants exclusive Hexvix rights to GE Healthcare; deal ends

Executive Summary

PhotoCure ASA (drugs and devices for cancer) has licensed GE Healthcare exclusive worldwide rights (outside of the US and Nordic countries) to market and distribute the imaging agent Hexvix (hexaminolevulinate) for the diagnosis and monitoring of bladder cancer. GE also gets an option for marketing and distribution in the US.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies